RACHEL TOWNSEND: Open Payments
NPI 1760116495 · BALTIMORE, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$621 in 51 payments from 10 companies in 2025. Trend: 2023 $64 · 2024 $248 · 2025 $621
Food & beverage: $621
| Company | Payments | Amount |
|---|---|---|
| Supernus Pharmaceuticals, Inc. | 29 | $137 |
| Lundbeck LLC | 5 | $130 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 5 | $116 |
| Vanda Pharmaceuticals Inc. | 3 | $68 |
| Otsuka America Pharmaceutical, Inc. | 3 | $64 |
| Lilly USA, LLC | 2 | $32 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $24 |
| Tris Pharma Inc | 1 | $19 |
| TMS NeuroHealth Centers Inc. | 1 | $16 |
| Janssen Pharmaceuticals, Inc | 1 | $14 |
Products named: REXULTI, Qelbree, CAPLYTA, HETLIOZ, TRINTELLIX, Dyanavel XR, JARDIANCE, TMS NeuroHealth Centers Inc..
Industry payments across MD — which companies pay providers there.
